Biogen, Sangamo partner to develop genome-editing therapies for Alzheimer’s and Parkinson’s disease
The drug maker Biogen announced it would license two preclinical drugs from Sangamo Therapeutics, both of which use a genome-editing technology called zinc fingers.
The drug maker Biogen announced late Thursday that it would license two preclinical drugs from Sangamo Therapeutics, both of which use a genome-editing technology called to regulate the expression of genes involved with neurological diseases like Alzheimer’s and Parkinson’s.
